Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 42

1.

Quantitative Analysis of Immune Infiltrates in Primary Melanoma.

Gartrell RD, Marks DK, Hart TD, Li G, Davari DR, Wu A, Blake Z, Lu Y, Askin KN, Monod A, Esancy CL, Stack EC, Jia DT, Armenta PM, Fu Y, Izaki D, Taback B, Rabadan R, Kaufman HL, Drake CG, Horst BA, Saenger YM.

Cancer Immunol Res. 2018 Apr;6(4):481-493. doi: 10.1158/2326-6066.CIR-17-0360. Epub 2018 Feb 21.

2.

MYC Overexpression at the Protein and mRNA Level and Cancer Outcomes among Men Treated with Radical Prostatectomy for Prostate Cancer.

Pettersson A, Gerke T, Penney KL, Lis RT, Stack EC, Pértega-Gomes N, Zadra G, Tyekucheva S, Giovannucci EL, Mucci LA, Loda M.

Cancer Epidemiol Biomarkers Prev. 2018 Feb;27(2):201-207. doi: 10.1158/1055-9965.EPI-17-0637. Epub 2017 Nov 15.

3.

Topological analysis reveals a PD-L1-associated microenvironmental niche for Reed-Sternberg cells in Hodgkin lymphoma.

Carey CD, Gusenleitner D, Lipschitz M, Roemer MGM, Stack EC, Gjini E, Hu X, Redd R, Freeman GJ, Neuberg D, Hodi FS, Liu XS, Shipp MA, Rodig SJ.

Blood. 2017 Nov 30;130(22):2420-2430. doi: 10.1182/blood-2017-03-770719. Epub 2017 Sep 11.

4.

Fatty Acid Synthase and Acetyl-CoA Carboxylase Are Expressed in Nodal Metastatic Melanoma But Not in Benign Intracapsular Nodal Nevi.

Saab J, Santos-Zabala ML, Loda M, Stack EC, Hollmann TJ.

Am J Dermatopathol. 2018 Apr;40(4):259-264. doi: 10.1097/DAD.0000000000000939.

PMID:
28654463
5.

Multiplexed tissue biomarker imaging.

Stack EC, Foukas PG, Lee PP.

J Immunother Cancer. 2016 Feb 16;4:9. doi: 10.1186/s40425-016-0115-3. eCollection 2016. No abstract available.

6.

Novel technologies and emerging biomarkers for personalized cancer immunotherapy.

Yuan J, Hegde PS, Clynes R, Foukas PG, Harari A, Kleen TO, Kvistborg P, Maccalli C, Maecker HT, Page DB, Robins H, Song W, Stack EC, Wang E, Whiteside TL, Zhao Y, Zwierzina H, Butterfield LH, Fox BA.

J Immunother Cancer. 2016 Jan 19;4:3. doi: 10.1186/s40425-016-0107-3. eCollection 2016. Review.

7.

Expression Levels of DNA Damage Repair Proteins Are Associated With Overall Survival in Platinum-Treated Advanced Urothelial Carcinoma.

Mullane SA, Werner L, Guancial EA, Lis RT, Stack EC, Loda M, Kantoff PW, Choueiri TK, Rosenberg J, Bellmunt J.

Clin Genitourin Cancer. 2016 Aug;14(4):352-9. doi: 10.1016/j.clgc.2015.12.029. Epub 2015 Dec 24.

8.

Evaluating a 4-marker signature of aggressive prostate cancer using time-dependent AUC.

Gerke TA, Martin NE, Ding Z, Nuttall EJ, Stack EC, Giovannucci E, Lis RT, Stampfer MJ, Kantoff PW, Parmigiani G, Loda M, Mucci LA.

Prostate. 2015 Dec;75(16):1926-33. doi: 10.1002/pros.23090. Epub 2015 Sep 7.

9.

Measuring PI3K Activation: Clinicopathologic, Immunohistochemical, and RNA Expression Analysis in Prostate Cancer.

Martin NE, Gerke T, Sinnott JA, Stack EC, Andrén O, Andersson SO, Johansson JE, Fiorentino M, Finn S, Fedele G, Stampfer M, Kantoff PW, Mucci LA, Loda M.

Mol Cancer Res. 2015 Oct;13(10):1431-40. doi: 10.1158/1541-7786.MCR-14-0569. Epub 2015 Jun 29.

10.

Comparing Platforms for Messenger RNA Expression Profiling of Archival Formalin-Fixed, Paraffin-Embedded Tissues.

Tyekucheva S, Martin NE, Stack EC, Wei W, Vathipadiekal V, Waldron L, Fiorentino M, Lis RT, Stampfer MJ, Loda M, Parmigiani G, Mucci LA, Birrer M.

J Mol Diagn. 2015 Jul;17(4):374-81. doi: 10.1016/j.jmoldx.2015.02.002. Epub 2015 Apr 30.

11.

DNA copy number analysis of metastatic urothelial carcinoma with comparison to primary tumors.

Bambury RM, Bhatt AS, Riester M, Pedamallu CS, Duke F, Bellmunt J, Stack EC, Werner L, Park R, Iyer G, Loda M, Kantoff PW, Michor F, Meyerson M, Rosenberg JE.

BMC Cancer. 2015 Apr 9;15:242. doi: 10.1186/s12885-015-1192-2.

12.

Multiplexed immunohistochemistry, imaging, and quantitation: a review, with an assessment of Tyramide signal amplification, multispectral imaging and multiplex analysis.

Stack EC, Wang C, Roman KA, Hoyt CC.

Methods. 2014 Nov;70(1):46-58. doi: 10.1016/j.ymeth.2014.08.016. Epub 2014 Sep 19. Review.

13.

Androgen receptor CAG repeat polymorphism and risk of TMPRSS2:ERG-positive prostate cancer.

Yoo S, Pettersson A, Jordahl KM, Lis RT, Lindstrom S, Meisner A, Nuttall EJ, Stack EC, Stampfer MJ, Kraft P, Brown M, Loda M, Giovannucci EL, Kantoff PW, Mucci LA.

Cancer Epidemiol Biomarkers Prev. 2014 Oct;23(10):2027-31. doi: 10.1158/1055-9965.EPI-14-0020. Epub 2014 Jun 12. Erratum in: Cancer Epidemiol Biomarkers Prev. 2015 Jan;24(1):318.

14.

FGFR3 expression in primary and metastatic urothelial carcinoma of the bladder.

Guancial EA, Werner L, Bellmunt J, Bamias A, Choueiri TK, Ross R, Schutz FA, Park RS, O'Brien RJ, Hirsch MS, Barletta JA, Berman DM, Lis R, Loda M, Stack EC, Garraway LA, Riester M, Michor F, Kantoff PW, Rosenberg JE.

Cancer Med. 2014 Aug;3(4):835-44. doi: 10.1002/cam4.262. Epub 2014 May 21.

15.

Neoadjuvant dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin with pegfilgrastim support in muscle-invasive urothelial cancer: pathologic, radiologic, and biomarker correlates.

Choueiri TK, Jacobus S, Bellmunt J, Qu A, Appleman LJ, Tretter C, Bubley GJ, Stack EC, Signoretti S, Walsh M, Steele G, Hirsch M, Sweeney CJ, Taplin ME, Kibel AS, Krajewski KM, Kantoff PW, Ross RW, Rosenberg JE.

J Clin Oncol. 2014 Jun 20;32(18):1889-94. doi: 10.1200/JCO.2013.52.4785. Epub 2014 May 12.

PMID:
24821883
16.

Activating mTOR mutations in a patient with an extraordinary response on a phase I trial of everolimus and pazopanib.

Wagle N, Grabiner BC, Van Allen EM, Hodis E, Jacobus S, Supko JG, Stewart M, Choueiri TK, Gandhi L, Cleary JM, Elfiky AA, Taplin ME, Stack EC, Signoretti S, Loda M, Shapiro GI, Sabatini DM, Lander ES, Gabriel SB, Kantoff PW, Garraway LA, Rosenberg JE.

Cancer Discov. 2014 May;4(5):546-53. doi: 10.1158/2159-8290.CD-13-0353. Epub 2014 Mar 13.

17.

Integrative analysis of 1q23.3 copy-number gain in metastatic urothelial carcinoma.

Riester M, Werner L, Bellmunt J, Selvarajah S, Guancial EA, Weir BA, Stack EC, Park RS, O'Brien R, Schutz FA, Choueiri TK, Signoretti S, Lloreta J, Marchionni L, Gallardo E, Rojo F, Garcia DI, Chekaluk Y, Kwiatkowski DJ, Bochner BH, Hahn WC, Ligon AH, Barletta JA, Loda M, Berman DM, Kantoff PW, Michor F, Rosenberg JE.

Clin Cancer Res. 2014 Apr 1;20(7):1873-83. doi: 10.1158/1078-0432.CCR-13-0759. Epub 2014 Jan 31.

18.

Modification of the association between obesity and lethal prostate cancer by TMPRSS2:ERG.

Pettersson A, Lis RT, Meisner A, Flavin R, Stack EC, Fiorentino M, Finn S, Graff RE, Penney KL, Rider JR, Nuttall EJ, Martin NE, Sesso HD, Pollak M, Stampfer MJ, Kantoff PW, Giovannucci EL, Loda M, Mucci LA.

J Natl Cancer Inst. 2013 Dec 18;105(24):1881-90. doi: 10.1093/jnci/djt332. Epub 2013 Nov 30.

19.

A co-clinical approach identifies mechanisms and potential therapies for androgen deprivation resistance in prostate cancer.

Lunardi A, Ala U, Epping MT, Salmena L, Clohessy JG, Webster KA, Wang G, Mazzucchelli R, Bianconi M, Stack EC, Lis R, Patnaik A, Cantley LC, Bubley G, Cordon-Cardo C, Gerald WL, Montironi R, Signoretti S, Loda M, Nardella C, Pandolfi PP.

Nat Genet. 2013 Jul;45(7):747-55. doi: 10.1038/ng.2650. Epub 2013 Jun 2.

20.

Phase 2 study of dose-intense temozolomide in recurrent glioblastoma.

Norden AD, Lesser GJ, Drappatz J, Ligon KL, Hammond SN, Lee EQ, Reardon DR, Fadul CE, Plotkin SR, Batchelor TT, Zhu JJ, Beroukhim R, Muzikansky A, Doherty L, Lafrankie D, Smith K, Tafoya V, Lis R, Stack EC, Rosenfeld MR, Wen PY.

Neuro Oncol. 2013 Jul;15(7):930-5. doi: 10.1093/neuonc/not040. Epub 2013 Apr 3.

21.

Opposing effects of androgen deprivation and targeted therapy on prostate cancer prevention.

Jia S, Gao X, Lee SH, Maira SM, Wu X, Stack EC, Signoretti S, Loda M, Zhao JJ, Roberts TM.

Cancer Discov. 2013 Jan;3(1):44-51. doi: 10.1158/2159-8290.CD-12-0262. Epub 2012 Dec 20.

22.

EZH2 oncogenic activity in castration-resistant prostate cancer cells is Polycomb-independent.

Xu K, Wu ZJ, Groner AC, He HH, Cai C, Lis RT, Wu X, Stack EC, Loda M, Liu T, Xu H, Cato L, Thornton JE, Gregory RI, Morrissey C, Vessella RL, Montironi R, Magi-Galluzzi C, Kantoff PW, Balk SP, Liu XS, Brown M.

Science. 2012 Dec 14;338(6113):1465-9. doi: 10.1126/science.1227604.

23.

The TMPRSS2:ERG rearrangement, ERG expression, and prostate cancer outcomes: a cohort study and meta-analysis.

Pettersson A, Graff RE, Bauer SR, Pitt MJ, Lis RT, Stack EC, Martin NE, Kunz L, Penney KL, Ligon AH, Suppan C, Flavin R, Sesso HD, Rider JR, Sweeney C, Stampfer MJ, Fiorentino M, Kantoff PW, Sanda MG, Giovannucci EL, Ding EL, Loda M, Mucci LA.

Cancer Epidemiol Biomarkers Prev. 2012 Sep;21(9):1497-509. doi: 10.1158/1055-9965.EPI-12-0042. Epub 2012 Jun 26.

24.

Genetic and functional analyses implicate the NUDT11, HNF1B, and SLC22A3 genes in prostate cancer pathogenesis.

Grisanzio C, Werner L, Takeda D, Awoyemi BC, Pomerantz MM, Yamada H, Sooriakumaran P, Robinson BD, Leung R, Schinzel AC, Mills I, Ross-Adams H, Neal DE, Kido M, Yamamoto T, Petrozziello G, Stack EC, Lis R, Kantoff PW, Loda M, Sartor O, Egawa S, Tewari AK, Hahn WC, Freedman ML.

Proc Natl Acad Sci U S A. 2012 Jul 10;109(28):11252-7. doi: 10.1073/pnas.1200853109. Epub 2012 Jun 22.

25.

Retromer disruption promotes amyloidogenic APP processing.

Sullivan CP, Jay AG, Stack EC, Pakaluk M, Wadlinger E, Fine RE, Wells JM, Morin PJ.

Neurobiol Dis. 2011 Aug;43(2):338-45. doi: 10.1016/j.nbd.2011.04.002. Epub 2011 Apr 16.

26.

A novel role for calcium/calmodulin kinase II within the brainstem pedunculopontine tegmentum for the regulation of wakefulness and rapid eye movement sleep.

Stack EC, Desarnaud F, Siwek DF, Datta S.

J Neurochem. 2010 Jan;112(1):271-81. doi: 10.1111/j.1471-4159.2009.06452.x. Epub 2009 Oct 26.

27.
28.

Evidence of oxidant damage in Huntington's disease: translational strategies using antioxidants.

Stack EC, Matson WR, Ferrante RJ.

Ann N Y Acad Sci. 2008 Dec;1147:79-92. doi: 10.1196/annals.1427.008. Review.

PMID:
19076433
29.

Combined riluzole and sodium phenylbutyrate therapy in transgenic amyotrophic lateral sclerosis mice.

Del Signore SJ, Amante DJ, Kim J, Stack EC, Goodrich S, Cormier K, Smith K, Cudkowicz ME, Ferrante RJ.

Amyotroph Lateral Scler. 2009 Apr;10(2):85-94. doi: 10.1080/17482960802226148.

PMID:
18618304
30.

Therapeutic attenuation of mitochondrial dysfunction and oxidative stress in neurotoxin models of Parkinson's disease.

Stack EC, Ferro JL, Kim J, Del Signore SJ, Goodrich S, Matson S, Hunt BB, Cormier K, Smith K, Matson WR, Ryu H, Ferrante RJ.

Biochim Biophys Acta. 2008 Mar;1782(3):151-62. doi: 10.1016/j.bbadis.2007.12.006. Epub 2008 Jan 16.

31.

Huntington's disease: progress and potential in the field.

Stack EC, Ferrante RJ.

Expert Opin Investig Drugs. 2007 Dec;16(12):1933-53. Review.

PMID:
18042002
32.

Neuroprotective effects of synaptic modulation in Huntington's disease R6/2 mice.

Stack EC, Dedeoglu A, Smith KM, Cormier K, Kubilus JK, Bogdanov M, Matson WR, Yang L, Jenkins BG, Luthi-Carter R, Kowall NW, Hersch SM, Beal MF, Ferrante RJ.

J Neurosci. 2007 Nov 21;27(47):12908-15.

33.

Modulation of nucleosome dynamics in Huntington's disease.

Stack EC, Del Signore SJ, Luthi-Carter R, Soh BY, Goldstein DR, Matson S, Goodrich S, Markey AL, Cormier K, Hagerty SW, Smith K, Ryu H, Ferrante RJ.

Hum Mol Genet. 2007 May 15;16(10):1164-75. Epub 2007 Apr 2.

PMID:
17403718
34.

Dose ranging and efficacy study of high-dose coenzyme Q10 formulations in Huntington's disease mice.

Smith KM, Matson S, Matson WR, Cormier K, Del Signore SJ, Hagerty SW, Stack EC, Ryu H, Ferrante RJ.

Biochim Biophys Acta. 2006 Jun;1762(6):616-26. Epub 2006 Apr 17.

35.

Combination therapy using minocycline and coenzyme Q10 in R6/2 transgenic Huntington's disease mice.

Stack EC, Smith KM, Ryu H, Cormier K, Chen M, Hagerty SW, Del Signore SJ, Cudkowicz ME, Friedlander RM, Ferrante RJ.

Biochim Biophys Acta. 2006 Mar;1762(3):373-80. Epub 2005 Dec 5.

36.

Chronology of behavioral symptoms and neuropathological sequela in R6/2 Huntington's disease transgenic mice.

Stack EC, Kubilus JK, Smith K, Cormier K, Del Signore SJ, Guelin E, Ryu H, Hersch SM, Ferrante RJ.

J Comp Neurol. 2005 Oct 3;490(4):354-70.

PMID:
16127709
37.

Genetic and pharmacological inactivation of the adenosine A2A receptor attenuates 3-nitropropionic acid-induced striatal damage.

Fink JS, Kalda A, Ryu H, Stack EC, Schwarzschild MA, Chen JF, Ferrante RJ.

J Neurochem. 2004 Feb;88(3):538-44.

38.

A functional neuroanatomical investigation of the role of the medial preoptic area in neural circuits regulating maternal behavior.

Stack EC, Balakrishnan R, Numan MJ, Numan M.

Behav Brain Res. 2002 Apr 1;131(1-2):17-36.

PMID:
11844569
40.

Morphometric studies of the aged hippocampus: I. Volumetric analysis in behaviorally characterized rats.

Rapp PR, Stack EC, Gallagher M.

J Comp Neurol. 1999 Jan 25;403(4):459-70.

PMID:
9888312
41.

2,5-Hexanedione alters elemental composition and water content of rat peripheral nerve myelinated axons.

LoPachin RM Jr, Lehning EJ, Stack EC, Hussein SJ, Saubermann AJ.

J Neurochem. 1994 Dec;63(6):2266-78.

PMID:
7964747
42.

Disruption of Schwann cell elemental composition is not a primary neurotoxic effect of 2,5-hexanedione.

LoPachin RM, Lehning EJ, Stack EC, Saubermann AJ.

Neurotoxicology. 1994 Winter;15(4):927-34.

PMID:
7715863

Supplemental Content

Loading ...
Support Center